Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting
- KRAS-specific synthetic lethal targets identified through Ryvu's ONCO Prime platform show promising potential for new therapeutic options for colorectal cancer (CRC) patients.
- RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant tumor growth inhibition in MTAP-deleted cancer models and enhances antitumor responses when combined with an anti-PD-1 antibody.
KRAKOW, Poland, March 26, 2025 / Biotech Newswire / -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced it will present preclinical data from its synthetic lethality pipeline at the 2025 AACR Annual Meeting, April 23-30, 2025, in Chicago, IL.
"We are excited to see continued progress across our preclinical pipeline. Our proprietary ONCO Prime platform has identified several novel synthetic lethal targets, including targets for KRAS-driven tumors, which offer immense potential to transform cancer treatment. Our work on next-generation ADCs targeting both synthetic lethality and immunocytotoxic mechanisms is advancing rapidly. At the same time, we continue to make significant strides in developing RVU305, our potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, with IND/CTA-enabling studies on track for completion in H2 2025. We are thrilled to present these advancements at the AACR Annual Meeting this year and look forward to engaging with the oncology community." - said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.
Details on the abstract presentations are as follows:
Abstract Title: “Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor,
shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment”
Session Name: HDAC and Methyltransferase Inhibitors
Session date and time: Tuesday, April 29, 9:00 AM - 12:00 PM EST
Poster Number: 17 (board number), abstract number 4231
RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant potential in targeting MTAP-deleted cancers. In preclinical studies, RVU305 effectively inhibited tumor growth in MTAP-null cancer models without affecting normal cells. Co-treatment with an anti-PD-1 antibody was well tolerated and resulted in antitumor activity in an MTAP-deleted, immune checkpoint inhibitors resistant model. The effects of RVU305, both alone and in combination with anti-PD-1, were supported by pharmacodynamic changes observed in tumor tissue. These results position RVU305 as a promising therapeutic option for patients carrying MTAP-deleted cancers resistant to immune checkpoint inhibitors treatment.
Abstract Title: “Discovery of novel synthetic lethal targets for effective and safe colorectal
cancer therapies”
Session Name: Experimental and Molecular Therapeutics
Session date and time: Monday, April 28, 2:00 PM - 5:00 PM EST
Poster Number: 3 (board number), abstract number 2973
This study highlights the discovery and validation of novel therapeutic targets for colorectal cancer (CRC) through synthetic lethal (SL) interactions, aiming to address the urgent need for more effective treatments. By using advanced models, including genetically engineered human intestinal stem cells (hISCs) and patient-derived xenografts (PDXs), combined with CRISPR/Cas9 technology, the team identified key vulnerabilities in CRC cells. Genome-wide screens revealed SL targets, particularly in genes associated with APC and KRAS mutations. These findings were validated both in vitro and in vivo, paving the way for the development of new, targeted therapies for CRC patients based on their unique mutational profiles.
All abstracts are now available online and can be obtained from the conference site:
https://www.aacr.org/
